Markets
Relmada Therapeutics Stock Plunges 11% After Hiring A Development Chief For Its Cancer Pipeline
The decline followed a 25% monthly rally, with the drug developer preparing an application for its next bladder-cancer trials.
Relmada Therapeutics (RLMD) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
The decline followed a 25% monthly rally, with the drug developer preparing an application for its next bladder-cancer trials.
SEC Filings
The new chief led ADSTILADRIN's pivotal program, while Relmada targets a year-end submission for its own bladder-cancer candidate.
Earnings
The CEO described two production approaches with encouraging stability data as Relmada prepares its U.S. trial application.
SEC Filings
Early bladder-cancer follow-up showed lasting responses, but two patients progressed to muscle-invasive disease.